Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 13/20 | 0.74 |
| ▸ | HTR2C | P28335 | 10/20 | 0.74 |
| ▸ | HTR2B | P41595 | 9/20 | 0.74 |
| ▸ | HTR1A | P08908 | 3/20 | 0.74 |
| ▸ | HTR6 | P50406 | 2/20 | 0.74 |
| ▸ | DRD1 | P21728 | 1/20 | 0.74 |
| ▸ | HTR1D | P28221 | 1/20 | 0.74 |
| ▸ | HTR1B | P28222 | 1/20 | 0.74 |
| ▸ | HTR1E | P28566 | 1/20 | 0.74 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.74 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.74 |
| ▸ | HTR7 | P34969 | 1/20 | 0.74 |
| ▸ | DRD3 | P35462 | 1/20 | 0.74 |
| ▸ | HTR5A | P47898 | 1/20 | 0.74 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29633090 | 1.00 | HTR2A (0.74) | HTR2AHTR2CHTR2BHTR1AHTR6 | |
| Hydrochloric Acid SCHEMBL29795110 | 0.99 | HTR2A (0.72) | HTR2AHTR2CHTR2BHTR1AHTR6 | |
| SCHEMBL26965684 | 0.88 | HTR2A (0.69) | HTR2AHTR2CHTR2BHTR1AHTR6 | |
| SCHEMBL29402695 | 0.87 | HTR2A (0.72) | HTR2AHTR2CHTR2BHTR1AHTR6 | |
| SCHEMBL4216851 | 0.87 | HTR2A (0.72) | HTR2AHTR2CHTR2BHTR1AHTR6 | |
| Hydrochloric Acid SCHEMBL4214418 | 0.86 | HTR2A (0.70) | HTR2AHTR2CHTR2BHTR1AHTR6 | |
| Hydrochloric Acid SCHEMBL29511162 | 0.86 | HTR2A (0.70) | HTR2AHTR2CHTR2BHTR1AHTR6 | |
| Psilocin SCHEMBL194899 | 0.85 | HTR2A (1.00) | HTR2AHTR2CHTR2BHTR1AHTR6 | |
| Psilocin SCHEMBL31188168 | 0.85 | HTR2A (1.00) | HTR2AHTR2CHTR2BHTR1AHTR6 | |
| Psilocin SCHEMBL29363508 | 0.85 | HTR2A (1.00) | HTR2AHTR2CHTR2BHTR1AHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 289 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260090957-A1 | Process for making aqueous therapeutic particle having stable exterior water clustering with nanosized thickness | DRESDNER JR KARL P (US) | 2026-04-02 | — | — | US | claimed |
| US-20250375421-A1 | METHODS OF USING DMT | SHULMAN WILLIAM (US) | 2025-12-11 | — | — | US | claimed |
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES INC (US) | 2025-11-27 | — | — | US | claimed |
| EP-4618980-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | Freedom Biosciences, Inc. (US) | 2025-09-24 | — | — | EP | claimed |
| EP-4618981-A1 | COMBINATIONS OF MONOAMINE OXIDASE INHIBITORS AND SEROTONIN RECEPTOR AGONISTS AND THEIR THERAPEUTIC USE | Remedi, Inc. (US) | 2025-09-24 | — | — | EP | claimed |
| EP-4615585-A1 | METHODS OF USING TRAZODONE TO REVERSE THE EFFECTS OF 5-HT2A RECEPTOR AGONISTS | Gilgamesh Pharmaceuticals, Inc. (US) | 2025-09-17 | — | — | EP | claimed |
| US-12396981-B2 | Methods of using DMT | SHULMAN WILLIAM (US) | 2025-08-26 | — | — | US | claimed |
| WO-2025099725-A1 | CONJUGATES AND USES THEREOF | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) | 2025-05-15 | — | — | WO | claimed |
| EP-4547250-A1 | METHODS AND COMPOSITIONS RELATING TO CONTROLLING PSYCHEDELIC EFFECTS WITH SEROTONIN RECEPTOR MODULATORS | Terran Biosciences Inc. (US) | 2025-05-07 | — | — | EP | claimed |
| US-20240398750-A1 | Methods of treating or reducing symptoms of anxiety, depression, attention deficiency (ADD), attention deficient hyperactivity (ADHD), obsessive compulsive (OCD), Bipolar disorder, and related disorders/conditions via combination therapy with vaccine/antibodies and 5ht1/5ht2, SERT and other allosteric modulators. | HELDRETH JR DAVID ALAN (US) | 2024-12-05 | — | — | US | claimed |
| WO-2023177294-A1 | TRANSMUCOSAL DELIVERY OF PSYCHOACTIVE COMPOUNDS | PLETHORA THERAPEUTICS B.V. (NL) | 2023-09-21 | — | — | WO | claimed |
| WO-2023028086-A1 | COMBINATIONS OF PERIPHERAL 5-HT2A RECEPTOR ANTAGONISTS AND CENTRAL 5-HT2A RECEPTOR AGONISTS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2023-03-02 | — | — | WO | claimed |
| WO-2022261263-A1 | METHODS OF TREATING NEUROPSYCHIATRIC DISORDERS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2022-12-15 | — | — | WO | claimed |
| WO-2022248635-A2 | METHODS FOR PRODUCING TRYPTAMINE DERIVATIVES. | OCTARINE BIO APS (DK) | 2022-12-01 | — | — | WO | claimed |
| WO-2022221942-A1 | PREVENTION OF DRUG DIVERSION | BETTERLIFE PHARMA INC. (CA) | 2022-10-27 | — | — | WO | claimed |
| WO-2022212854-A1 | METHODS AND COMPOSITIONS RELATING TO PSYCHEDELICS AND SEROTONIN RECEPTOR MODULATORS | TERRAN BIOSCIENCES INC. (US) | 2022-10-06 | — | — | WO | claimed |
| WO-2022082058-A1 | METHOD OF TREATMENT BY TRYPTAMINE ALKALOIDS | ELEUSIS THERAPEUTICS US, INC. (US) | 2022-04-21 | — | — | WO | claimed |
| EP-3762498-A1 | PROCESSES FOR THE PRODUCTION OF TRYPTAMINES | New Atlas Biotechnologies LLC (US) | 2021-01-13 | — | — | EP | claimed |
| CN-112105734-A | Method for producing tryptamine | 新图集生物技术有限责任公司 | 2020-12-18 | — | — | CN | claimed |
| WO-2019173797-A1 | PROCESSES FOR THE PRODUCTION OF TRYPTAMINES | NEW ATLAS BIOTECHNOLOGIES LLC (US) | 2019-09-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12396981-B2 | Methods of using DMT | PNMT, HTR6, HTR1A | HTR2A 5/4885HTR2C 14/4885HTR2B 16/4885 |
| US-20250375421-A1 | METHODS OF USING DMT | PNMT, HTR6, HTR1A | HTR2A 5/4885HTR2C 14/4885HTR2B 16/4885 |
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | PDE9A, PDE3A, PDE2A | HTR2A 14/4885HTR2C 42/4885HTR2B 28/4885 |
| US-20260090957-A1 | Process for making aqueous therapeutic particle having stable exterior water clustering with nanosized thickness | QPCT, SLC38A7, QPCTL | HTR2A 2610/4885HTR2C 1076/4885HTR2B 3639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.